ReviewCardiology clinics2016
World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.
Review in Cardiology clinics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05207683 (Pulmonary Hypertension in Patients Attending Sohag University Hospital), which is not on this map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pulmonary Hypertension in Patients Attending Sohag University Hospital: A Focus on The Etiology
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Impact of BMPR2 mutation on the severity of pulmonary arterial hypertension: a systematic review and meta-analysis.Respiratory research · 2025Pooled it
- Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.Annals of the rheumatic diseases · 2020Trial
- GCN2 in proteostasis: structural logic, signalling networks and disease.The FEBS journal · 2026Review
- Pulmonary Arterial Hypertension in Octogenarians: The Pulmonary Hypertension Association Registry.Pulmonary circulation · 2026Article
- Epidemiological patterns of pulmonary hypertension at 3,658 meters: insights from a Tibet plateau retrospective study.Journal of thoracic disease · 2026Article
- Loss of Brg1 prevents the progression of pulmonary hypertension by inhibiting Nrf2 expression.Scientific reports · 2026Article
- Article
- Plasma GDF-15 and PSP-D Predict the Development of Pulmonary Arterial Hypertension in Systemic Sclerosis.Pulmonary circulation · 2026Article
- Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study.Drugs - real world outcomes · 2025Article
- Macrophage plasticity and glucose metabolism: the role of immunometabolism in pulmonary arterial hypertension.Clinical science (London, England : 1979) · 2025Review
- Severity Classification of Functional Impairment Based on ICF Qualifiers: A New Proposal for Assessing Individuals With Pulmonary Hypertension.Physiotherapy research international : the journal for researchers and clinicians in physical therapy · 2025Observational
- Examining the Disproportionate Burden of Microvascular Disease in Women.Current atherosclerosis reports · 2025Review
- Improving Care for People with Chronic Respiratory Diseases: Taking a Policy Lens.Advances in therapy · 2025Review
- Female Fibroblast Activation Is Estrogen-Mediated in Sex-Specific 3D-Bioprinted Pulmonary Artery Adventitia Models.ACS biomaterials science & engineering · 2025Article
- Intranasal delivery of R8-modified circNFXL1 liposomes ameliorates Su5416-induced pulmonary arterial hypertension in C57BL/6 mice.Respiratory research · 2025Article
- Morbidity and Mortality Associated With Pulmonary Arterial Hypertension in a Schistosomiasis-Endemic Region of Brazil.Pulmonary circulation · 2025Article
- Inhibition of Sodium/Hydrogen Exchanger-1 in the Right Ventricle and Lung Dysfunction Induced by Experimental Pulmonary Arterial Hypertension in Rats.Journal of the American Heart Association · 2025Article
- Trends in pulmonary arterial hypertension: insights from Global Burden of Disease 1990-2021.BMJ open · 2025Article
- SMAD5 as a novel gene for familial pulmonary arterial hypertension.Clinical science (London, England : 1979) · 2025Article
- The disproportionate burden of pulmonary arterial hypertension among the elderly: global, regional, and national trends from 1990 to 2021-findings from the 2021 global burden of disease study.Frontiers in cardiovascular medicine · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a debilitating disease characterized by pathologic remodeling of the resistance pulmonary arteries, ultimately leading to right ventricular (RV) failure and death. In this article we discuss the definition of PAH, the initial epidemiology based on the National Institutes of Health Registry, and the updated epidemiology gleaned from contemporary registries, pathogenesis of pulmonary vascular dysfunction and proliferation, and RV failure in PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.